Search results
On doorstep of approval, Merck compares V116 pneumococcal vaccine to 1983 warhorse Pneumovax 23
FierceBiotech· 11 hours agoFive months ago, Merck revealed data that indicate its next-generation pneumococcal vaccine offers more protection for older adults than Pfizer’s market dominator Prevnar ...
FDA Says Vaccination Is the Best Protection Against Measles
Sierra Sun Times· 11 hours agoMeasles is one of the most contagious respiratory diseases in the world that has the potential to be life-threatening. Vaccines approved by the U.S. Food and Drug Administration ...
Should You Buy Moderna Before May 12?
Motley Fool via Yahoo Finance· 4 days agoThe biotech company aims to bring as many as 15 new products to market over the next five years and has the late-stage pipeline to support...is set to...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 5 days agoThe RS Rating is a 1-99 measure of a stock's 12-month performance. This means Moderna stock outranks...
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 5 days agoThe RS Rating measures a stock's 12-month running performance against all other stocks. That RS...
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for...
Morningstar· 7 days agoImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Designated ...
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer
Nature· 4 days agoDiscover the world’s best science and medicine | Nature.com
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks via Yahoo Finance· 3 days agoNovartis’ Lutathera Gets FDA Nod for Rare Cancer in Kids: The FDA granted approval to Novartis’...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 4 days agoQuarter in Detail The Pharmaceutical segment generated revenues of $14.0 billion, up 9% year over...
Merck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly Beat
Investor's Business Daily· 4 days agoMerck noted that the devaluation of the Argentine peso had a 2% impact on sales. Minus that factor,...